InfuSystem and Sanara MedTech have secured an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC to deliver the Chemo Mouthpiece®, an oral cryotherapy device aimed at alleviating oral mucositis for cancer patients.

Target Overview

ChemoMouthpiece, LLC is a privately held medical device company that specializes in the development and commercialization of proprietary oral cryotherapy products specifically designed for cancer patients. The company was founded by David Yoskowitz, who, having experienced oral mucositis firsthand during his treatment for Hodgkin's Lymphoma, sought to create a more effective solution for managing this painful condition. The resultant Chemo Mouthpiece® device, which utilizes cryotherapy, has received FDA 510(k) clearance and is designed to alleviate the symptoms of oral mucositis by cooling the oral cavity and reducing the flow of chemotherapy to the area.

Industry Overview

In the United States, oral mucositis is recognized as a prevalent complication faced by cancer patients undergoing stomatotoxic chemotherapy treatments, impacting an estimated 500,000 to 1,000,000 patients annually. The condition is characterized by painful mouth ulcers, making it a significant concern for oncology care providers. With the annual market size projected to exceed $600 million, the treatment of oral mucositis is vital to improving patient quality of life and the effectiveness of ongoing cancer therapies.

The introduction of innovative products, like the Chemo Mouthpiece®, is critical in this context, especially as the American Medical Association recently issued a CPT code to facilitate potential reimbursement for healthcare providers offe